Literature DB >> 15210761

The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells.

Christine M Seroogy1, Luis Soares, Erik A Ranheim, Leon Su, Claire Holness, Debra Bloom, C Garrison Fathman.   

Abstract

Acquisition of the anergy phenotype in T cells is blocked by inhibitors of protein synthesis and calcineurin activity, suggesting that anergic T cells may have a unique genetic program. Retroviral transduction of hemopoietic stem cells from TCR transgenic mice and subsequent reconstitution of syngeneic mice to express the E3 ubiquitin ligase, gene related to anergy in lymphocytes (GRAIL), or an enzymatically inactive form, H2N2 GRAIL, allowed analysis of the role of GRAIL in T cell anergy in vivo. Constitutive expression of GRAIL was sufficient to render naive CD4 T cells anergic, however, when the enzymatically inactive form H2N2 GRAIL was expressed, it functioned as a dominant negative of endogenous GRAIL and blocked the development of anergy. These data provide direct evidence that a biochemical pathway composed of GRAIL and/or GRAIL-interacting proteins is important in the development of the CD4 T cell anergic phenotype in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210761     DOI: 10.4049/jimmunol.173.1.79

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 2.  GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Authors:  Chan C Whiting; Leon L Su; Jack T Lin; C Garrison Fathman
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

Review 3.  Molecular mechanisms for adaptive tolerance and other T cell anergy models.

Authors:  Seeyoung Choi; Ronald H Schwartz
Journal:  Semin Immunol       Date:  2007-04-02       Impact factor: 11.130

Review 4.  Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Gene related to anergy in lymphocytes (GRAIL) expression in CD4+ T cells impairs actin cytoskeletal organization during T cell/antigen-presenting cell interactions.

Authors:  Jill M Schartner; William T Simonson; Sarah A Wernimont; Lauren M Nettenstrom; Anna Huttenlocher; Christine M Seroogy
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

6.  Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis.

Authors:  Y-C Chen; J Y-H Chan; Y-L Chiu; S-T Liu; G Lozano; S-L Wang; C-L Ho; S-M Huang
Journal:  Cell Death Differ       Date:  2013-02-01       Impact factor: 15.828

7.  Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism.

Authors:  Kenneth D Bishop; John E Harris; John P Mordes; Dale L Greiner; Aldo A Rossini; Michael P Czech; Nancy E Phillips
Journal:  Cell Immunol       Date:  2009-02-23       Impact factor: 4.868

8.  T-cell regulator RNF125/TRAC-1 belongs to a novel family of ubiquitin ligases with zinc fingers and a ubiquitin-binding domain.

Authors:  Ana Lucia Giannini; Yifang Gao; Marie-José Bijlmakers
Journal:  Biochem J       Date:  2008-02-15       Impact factor: 3.857

9.  IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes.

Authors:  Myrianne Duré; Fernando Macian
Journal:  Mol Immunol       Date:  2008-11-05       Impact factor: 4.407

10.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.